RU2007120254A - Новые способы применения агонистов эстрогена бета - Google Patents

Новые способы применения агонистов эстрогена бета Download PDF

Info

Publication number
RU2007120254A
RU2007120254A RU2007120254/14A RU2007120254A RU2007120254A RU 2007120254 A RU2007120254 A RU 2007120254A RU 2007120254/14 A RU2007120254/14 A RU 2007120254/14A RU 2007120254 A RU2007120254 A RU 2007120254A RU 2007120254 A RU2007120254 A RU 2007120254A
Authority
RU
Russia
Prior art keywords
carbon atoms
alkyl
halogen
alkenyl
carbon
Prior art date
Application number
RU2007120254/14A
Other languages
English (en)
Russian (ru)
Inventor
Марк ДЭЙ (US)
Марк ДЭЙ
Хизер А ХАРРИС (US)
Хизер А ХАРРИС
Original Assignee
Вайет (Us)
Вайет
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Вайет (Us), Вайет filed Critical Вайет (Us)
Publication of RU2007120254A publication Critical patent/RU2007120254A/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A61K31/055—Phenols the aromatic ring being substituted by halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
RU2007120254/14A 2004-12-17 2005-12-15 Новые способы применения агонистов эстрогена бета RU2007120254A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63714404P 2004-12-17 2004-12-17
US60/637,144 2004-12-17

Publications (1)

Publication Number Publication Date
RU2007120254A true RU2007120254A (ru) 2009-01-27

Family

ID=36143266

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2007120254/14A RU2007120254A (ru) 2004-12-17 2005-12-15 Новые способы применения агонистов эстрогена бета

Country Status (20)

Country Link
US (1) US20060135574A1 (cg-RX-API-DMAC7.html)
EP (1) EP1824478A2 (cg-RX-API-DMAC7.html)
JP (1) JP2008524236A (cg-RX-API-DMAC7.html)
KR (1) KR20070086329A (cg-RX-API-DMAC7.html)
CN (1) CN101321524A (cg-RX-API-DMAC7.html)
AR (1) AR051844A1 (cg-RX-API-DMAC7.html)
AU (1) AU2005316561A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0519111A2 (cg-RX-API-DMAC7.html)
CA (1) CA2590258A1 (cg-RX-API-DMAC7.html)
GT (1) GT200500370A (cg-RX-API-DMAC7.html)
IL (1) IL183604A0 (cg-RX-API-DMAC7.html)
MX (1) MX2007007347A (cg-RX-API-DMAC7.html)
NI (1) NI200700152A (cg-RX-API-DMAC7.html)
NO (1) NO20072658L (cg-RX-API-DMAC7.html)
PA (1) PA8656601A1 (cg-RX-API-DMAC7.html)
PE (1) PE20061113A1 (cg-RX-API-DMAC7.html)
RU (1) RU2007120254A (cg-RX-API-DMAC7.html)
TW (1) TW200637545A (cg-RX-API-DMAC7.html)
WO (1) WO2006065968A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200705103B (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1984028A2 (en) * 2006-02-14 2008-10-29 Wyeth a Corporation of the State of Delaware Aqueous pharmaceutical formulations of er selective ligands
WO2010105035A2 (en) * 2009-03-11 2010-09-16 University Of South Florida Prevention, treatment, and diagnosis of alzheimer's disease through electromagnetic field exposure
US10149982B2 (en) 2009-03-11 2018-12-11 University Of South Florida Prevention and treatment of brain diseases and disorders related to abnormal protein aggregation through electromagnetic field treatment
US10758496B2 (en) * 2014-09-02 2020-09-01 The Regents Of The University Of California Estrogen receptor ligand treatment for neurodegenerative diseases
WO2018183800A1 (en) * 2017-03-30 2018-10-04 Marquette University Substituted (4'-hydroxyphenyl)cycloalkane and (4'-hydroxyphenyl)cycloalkene compounds and uses thereof as selective agonists of the estrogen receptor beta isoform for enhanced memory consolidation

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5990078A (en) * 1995-07-14 1999-11-23 The Trustees Of Columbia University In The City Of New York Means of increasing estrogen receptor levels in neural tissue
FR2739777B1 (fr) * 1995-10-11 1997-11-14 Cird Galderma Ligand antagoniste rar-gamma ou agoniste rar-alpha en tant qu'inhibiteur d'apoptose
WO1998021946A1 (en) * 1996-11-18 1998-05-28 Internutria, Inc. Composition and treatment for persistent reproductive transition symptoms
US20040092010A1 (en) * 2002-04-15 2004-05-13 Ariel Ruiz I Altaba Method of proliferating and inducing brain stem cells to differentiate to neurons
TR200102992T2 (tr) * 1999-04-16 2004-12-21 Astrazeneca Ab ß östrojen reseptörü ligandları.
JP2004515496A (ja) * 2000-12-07 2004-05-27 アストラゼネカ・アクチエボラーグ ベンズイミダゾール治療剤
WO2002051821A1 (en) * 2000-12-22 2002-07-04 Astrazeneca Ab Therapeutic compounds
US20030096264A1 (en) * 2001-06-18 2003-05-22 Psychiatric Genomics, Inc. Multi-parameter high throughput screening assays (MPHTS)
DE60116109T2 (de) * 2001-11-07 2006-09-07 Schering Ag In vitro Screening nach Liganden des Östrogenrezeptors
UA83620C2 (ru) * 2001-12-05 2008-08-11 Уайт Замещенные бензоксазолы и их аналоги как эстрогенные агенты
TWI306450B (en) * 2001-12-13 2009-02-21 Wyeth Corp Substituted phenyl naphthalenes as estrogenic agents
TW200301107A (en) * 2001-12-13 2003-07-01 Wyeth Corp Substituted 6H-dibenzo[c,h]chromenes as estrogenic agents
US6774248B2 (en) * 2001-12-18 2004-08-10 Wyeth Substituted 2-phenyl benzofurans as estrogenic agents
WO2004026290A1 (en) * 2002-09-19 2004-04-01 Merck & Co., Inc. Method for treating depression and/or anxiety
CL2004000985A1 (es) * 2003-05-16 2005-01-14 Wyeth Corp Compuestos derivados de fenilquinolinas; composicion farmaceutica, proceso de preparacion; y uso para tratar osteoporosis, enfermedad de paget, dano vascular, osteoartritis, cancer oseo, cancer ovarico, cancer prostatico, hipercolesterolemia, aterosc
US7157492B2 (en) * 2004-02-26 2007-01-02 Wyeth Dibenzo chromene derivatives and their use as ERβ selective ligands
JP2008505095A (ja) * 2004-07-01 2008-02-21 ワイス エストロゲンリガンドとしての四環式化合物

Also Published As

Publication number Publication date
BRPI0519111A2 (pt) 2008-12-23
CN101321524A (zh) 2008-12-10
PA8656601A1 (es) 2006-12-07
AR051844A1 (es) 2007-02-14
WO2006065968A8 (en) 2008-09-12
IL183604A0 (en) 2007-10-31
AU2005316561A1 (en) 2006-06-22
MX2007007347A (es) 2007-07-13
NO20072658L (no) 2007-09-12
WO2006065968A2 (en) 2006-06-22
PE20061113A1 (es) 2006-11-06
CA2590258A1 (en) 2006-06-22
WO2006065968A3 (en) 2008-04-10
TW200637545A (en) 2006-11-01
GT200500370A (es) 2006-07-13
NI200700152A (es) 2008-06-17
KR20070086329A (ko) 2007-08-27
JP2008524236A (ja) 2008-07-10
EP1824478A2 (en) 2007-08-29
ZA200705103B (en) 2009-11-25
US20060135574A1 (en) 2006-06-22

Similar Documents

Publication Publication Date Title
Haus et al. Biological clocks and shift work: circadian dysregulation and potential long-term effects
RU2003124653A (ru) Производные пурина в качестве антагонистов пуринергических рецепторов
JP6352413B2 (ja) 感覚的不快感の治療向け局所薬としてのジ−イソプロピル−アルカン(dapa)化合物
JP2001527068A5 (cg-RX-API-DMAC7.html)
EP2254577A1 (en) Ampa receptor antagonists for epilepsy, mental disorders or deficits in sensory organ
JP2015514679A5 (cg-RX-API-DMAC7.html)
RU2011149637A (ru) Феноксиметильные гетероциклические соединения
WO2009054544A1 (en) Ampa receptor antagonists for parkinson's disease and movement disorders
Volkan et al. Known object loss, disturbance in reality testing, and “ee-grief work” as a method of brief psychotherapy
DE69936994T2 (de) Verfahren zur behandlung von okularen neovaskularen erkrankungen
KR950702551A (ko) 염증 및 면역 질환의 치료용 2,5-디아릴 테트라히드로티오펜, 2,5-디아릴 테트라히드로푸란 및 그 유사물(2,5-diaryl tetrahydro-thiophene, furans and analogs for the treatment of inflamimatory and immune disorders)
JP2008524236A5 (cg-RX-API-DMAC7.html)
AU2004204814A1 (en) Method of treating cognitive decline due to sleep deprivation and stress
Misra et al. Pharmacotherapy of insomnia and current updates
KR102301073B1 (ko) 시노카브 또는 이의 약학적으로 허용가능한 염을 포함하는 약학적 조성물 및 이를 이용하여 운동이상증 및 관련 장애를 치료하는 방법
Schlebusch, L., Pillay, BJ & Louw Depression and self-report disclosure after live related donor and cadaver renal transplants
TW201440769A (zh) N-2-羥基-乙基-六氫吡-n’-2-乙磺酸(hepes)之止痛及反轉髓鞘脫失損傷用途
Levay et al. Concurrent sex therapy and psychoanalytic psychotherapy by separate therapists: Effectiveness and implications
CN115671188A (zh) 一种眼睛主动吸收氨基酸技术配方
Levine Helping men to control ejaculation
Reddy Psychological approach to ejaculatory disorders
Bitzer Definition and diagnosis of sexual problems
Das et al. Intermittent theta burst stimulation using H7 coil for management of negative symptoms and cognitive dysfunction in chronic schizophrenia: A case report
Jasiński The psychological difficulties of adapting to the aging process
Barbee et al. Psychological aspects of vitiligo in negroes

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20100419